These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31627060)

  • 21. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance.
    Zhang Y; Wang L; Zhang Q; Zhu G; Zhang Z; Zhou X; Chen Y; Lu T; Tang W
    J Chem Inf Model; 2017 Jun; 57(6):1439-1452. PubMed ID: 28485964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF
    Wang CR; Wang ZF; Shi L; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2382-2390. PubMed ID: 29934244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
    Lyne PD; Aquila B; Cook DJ; Dakin LA; Ezhuthachan J; Ioannidis S; Pontz T; Su M; Ye Q; Zheng X; Block MH; Cowen S; Deegan TL; Lee JW; Scott DA; Custeau D; Drew L; Poondru S; Shen M; Wu A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1026-9. PubMed ID: 19097792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
    Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
    Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells.
    Ragab FAF; Abdel-Aziz SA; Kamel M; Ouf AMA; Allam HA
    Bioorg Chem; 2019 Dec; 93():103323. PubMed ID: 31586713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma.
    Khormi AY; Farghaly TA; Bayazeed A; Al-Ghamdi YO; Abdulwahab HG; Shaaban MR
    RSC Adv; 2022 Sep; 12(42):27355-27369. PubMed ID: 36276003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
    Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents.
    El-Damasy AK; Seo SH; Cho NC; Pae AN; Kim EE; Keum G
    Chem Biol Drug Des; 2017 Jan; 89(1):98-113. PubMed ID: 27496071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
    Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
    Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imidazo[1,2-
    Chouchou A; Patinote C; Cuq P; Bonnet PA; Deleuze-Masquéfa C
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30445763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
    El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
    Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
    Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
    J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis,
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1534-1543. PubMed ID: 31452407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
    Eur J Med Chem; 2016 Aug; 119():122-31. PubMed ID: 27155467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.